“We are also encouraged to see that nearly all eligible participants are rolling over into the long-term extension of the INVOKE-2 trial, which will enable us to better understand the long-term effects of this potential therapeutic. Notably, results from a Phase 1 clinical...
“The continued development of ELI-002 is supported by encouraging clinical results that have demonstrated a favorable safety profile, a strong correlation between T-cell response, tumor biomarker reductions and reduced risk of recurrence or death.” REFERENCES: Elicio Therapeutics reaches alignment with...
To guide human clinical dose and regimen selection, and to estimate safety margins for the first-in-human phase 1 trial of AL002, we performed a 4-week GLP toxicology study in cynomolgus monkeys. IV administration of AL002 at doses up to 250 mg/kg weekly for 4 weeks was well tolerated,...
Objective: We report on the risk of miscarriage with high- and low-dosage periconceptional folic acid (FA) supplementation from a double-blind randomized clinical trial for prevention of orofacial cleft recurrence in Brazil.Methods: Women at risk of recurrence of orofacial clefts in their offspr...
A randomized controlled trial of the effect of real-time telemedicine support on glycemic control in young adults with type 1 diabetes (ISRCTN 46889446). To determine whether a system of telemedicine support can improve glycemic control in type 1 diabetes. A 9-month randomized trial compared ...
However, a randomized Phase II trial of PMX + irinotecan (ALIRI) showed similar efficacy and safety, but significantly shorter progression-free survival (PFS) compared with FOLFIRI in locally advanced or metastatic CRC. In our previous aCGH study, we evaluated genome-wide copy number variations...